The clinical symptoms of human malaria are mediated, at least in part, by the release of tumor necrosis factor alpha (TNF) by monocytes and macrophages. We have found that lysates of Plasmodium falciparuminfected erythrocytes stimulate the secretion of TNF from human mononuclear cells, and we have generated several immunoglobulin M monoclonal antibodies (MAbs) that inhibit the induction of TNF by such lysates. Here we describe the properties of MAb 5AB3-11, which causes dose-dependent inhibition of the TNF-inducing factors derived from P. fakiparum-infected erythrocytes, with a 50%o reduction in TNF secretion at nanomolar concentrations (1 to 2 ,ug/ml). The inhibitory effect appears to be malaria specific in that the induction of TNF by either lipopolysaccharide or lipoteichoic acid is not affected. MAb 5AB3-11 binds to liposomes containing phosphatidylinositol but not to other phospholipid liposomes, showing that it recognizes a phosphatidylinositol-like epitope. MAb 5AB3-11 inhibits the induction of TNF by whole lysates from several strains of P. fakciparum which originated from different parts of the tropics, indicating that all of the major TNF-inducing factors derived from Plasmodium-infected erythrocytes contain a common epitope. A phosphatidylinositol-like epitope expressed by Plasmodium-infected erythrocytes may be a suitable immunological target for the prevention or treatment of severe malaria.
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Tumor necrosis factor alpha (TNF) plays an important role in the pathology of human malaria. It has been shown to be a critical mediator of malaria fever, which is the most common clinical manifestation of Plasmodium infections. In patients infected with Plasmodium vivax, malarial fever paroxysms are associated with a sharp rise in plasma concentrations of TNF (12) , and in patients infected with P. falciparum, an anti-TNF monoclonal antibody (MAb) reduces fever (17) . Clinical studies have also shown that fatal cerebral malaria is associated with very high TNF levels, suggesting that TNF has a role in the pathophysiology of this condition (11, 13, 16) . Experimental studies have revealed several potential mechanisms for this association, including TNF-induced upregulation of endothelial cell adhesion molecules that mediate parasite sequestration (8) and possibly cytokine-induced generation of nitric oxide from endothelium (14) .
These observations raise the possibility that strategies to prevent excessive TNF production might be of value in the prevention or treatment of cerebral malaria, which presently has a case fatality rate of around 15% (9) . In this paper, we consider the feasibility of immunologically inhibiting the critical parasite-derived components that are responsible for stimulating the host TNF response. This approach has previously been used in the treatment of septic shock caused by gram-negative bacteria. Gram-negative bacteria contain lipopolysaccharide (LPS), which is a powerful stimulant of TNF production. A MAb that binds to lipid A, the biologically active component of LPS, has been shown to inhibit TNF production by LPS derived from different bacteria in vitro (10) and to protect mice challenged with gram-negative bacteria (18) .
We have previously shown that Plasmodium-infected erythrocytes stimulate TNF production by macrophages (6) . Since Plasmodium-infected erythrocytes contain factors that are functionally similar to endotoxin (LPS), we refer to them as malaria toxins. When mice are immunized with Plasmodium lysates or with phosphatidylinositol (PI), they produce immunoglobulin M (IgM) antibodies which inhibit TNF secretion in response to malaria toxins (3, 4) . We have recently found evidence that a similar type of IgM antibody response is produced by humans exposed to malaria (2) . To extend our understanding of the immune response to the biologically active components of the malaria toxins, we have raised a number of inhibitory murine MAbs. Here we describe the properties of MAb 5AB3-11, which was raised after immunization with PI conjugated to keyhole limpet hemocyanin (KLH). We have used this MAb to address the question of whether the TNF-inducing properties of different strains of parasite can be attributed to a single type of biologically active moiety.
MATERUILS AND METHODS
Immunization and fusions. Groups of (C57BL x BALB/ c)F1 female mice at least 10 weeks old were immunized with either lysates of P. falciparum-infected erythrocytes, or PI (from bovine liver; Sigma) conjugated to KLH (Calbiochem), using l-ethyl-3-(3-dimethylamino-propyl) carbodiimide methiodide (Sigma) as previously described (5) . Both of these immunization regimens had been shown to stimulate the production of inhibitory antibodies (5). Three to 5 days after the third injection, spleens were removed from a mouse from each group and teased apart under sterile conditions. Cell suspensions were collected and resuspended with mouse myeloma NS-1/1-Ag4-1 cells growing in log phase at a ratio of 5:1. Fusion was performed with 50% (wt/vol) polyethylene glycol 1500 (Boehringer Mannheim) according to standard procedures. As soon as hybridoma growth was macroscopically visible, supernatants were screened for the ability to inhibit TNF production by human peripheral blood mononuclear cells stimulated with lysates of P. falciparum-infected erythrocytes, as described below. Cloning of positive cultures was carried out by limiting dilution in the presence of 15% fetal calf serum containing 10% EMA conditioned medium (Boehringer Mannheim). Two further rounds of cloning by limiting dilution were carried out to ensure the clonality of the hybridomas described here.
Purification of MAbs. Hybridoma supernatants or control preparations of normal mouse serum diluted 1:10 were spun at 2,000 x g and filtered. They were then applied to an isotypespecific affinity column containing goat anti-mouse IgM bound to agarose (Sigma). The columns were washed extensively with 0.1 M glycine HCl at pH 5 to remove contaminants and then with sterile phosphate-buffered saline (PBS). The IgM fraction was eluted with 0.1 M glycine HCl at pH 2.5, immediately neutralized with 100 mM Tris buffer at pH 8, concentrated to 1 mg/ml with 100-kDa Centricon filters (Amicon), dialyzed against PBS, filtered, and stored at 4°C prior to testing. Protein concentrations were determined by Micro bicinchoninic acid protein assay kit (Pierce). Several control IgM MAbs were purified from hybridoma supernatants without inhibitory activity, and one was obtained from Sigma.
Parasite preparations. For immunization and screening of hybridoma supernatants, we used R29, a cloned laboratory line of P. falciparum derived from the Brazilian isolate IT14/4/25. This was cultured in human group 0 erythrocytes, using RPMI 1640 containing 2 g of glucose per liter and 10% A' human serum (22) . Preparations of mature trophozoites and schizonts at a parasitemia of -10% were harvested by centrifugation at 10,000 x g for 10 min. The supernatant was removed, and the remaining pellet was lysed by the addition of 4 volumes of water and stored at -20°C prior to testing. For most experiments we used partially purified preparations of these lysates, from which nonstimulatory components had been removed by washing the pellet in PBS and then in a mixture of methanolchloroform-water (8:4:3) . Where indicated in the text, partially purified preparations were digested further with 100 ,g of mixed proteases (pronase E; Sigma) per ml.
To investigate the inhibitory activity of MAbs against different parasite strains, we compared R29 with three other lines derived from IT 14/4/25 (IT04, A4, and C28) (20) , as well as Malayan Camp, the Gambian strain FCR3A2, the Thai strain T996, and a Kenyan wild isolate (Kilifi 0303).
TNF production assay. Blood from healthy European volunteers was collected in heparinized containers and mixed with an equal volume of saline before mononuclear cells were isolated on Lymphoprep (Nyegaard). Peripheral blood mononuclear cells were washed three times, resuspended in RPMI 1640 containing 1% A' human serum, and dispensed into flat-bottomed, 96-well microtiter plates at 105 cells per well. After 1 h at 37°C, nonadherent cells were removed by gentle washing, and then inhibitors were added followed by stimulants, all diluted in RPMI 1640, to a total volume of 200 ,u. Titrations of LPS from Escherichia coli 055:B5 or lipoteichoic acid from Streptococcuspyogenes (Sigma) were used as positive controls. After overnight incubation in 5% CO2 at 37°C, the supernatants were harvested and assayed for TNF by an enzyme-linked immunosorbent assay (ELISA), as described previously (16) .
For certain experiments we used the human monocytemacrophage cell line Mono Mac 6 (19 (Fig. 1A) . When P. falciparum lysates were titrated in the presence and absence of MAb 5AB3-11 at 25 ,ug/ml, it was found that 50 times as much toxin was needed to stimulate a given level of TNF when the MAb was present (Fig. 1B) . (Fig. 2) . Furthermore, MAb 5AB3-11 did not bind to either phorbol myristate acetate-activated Mono Mac 6 cells or human mononuclear cells in adsorption experiments (data not shown).
MAb 5AB3-11 does not inhibit LPS-or lipoteichoic acidinduced TNF secretion. To see if the inhibitory effect of MAb 5AB3-11 is specific, we tested its ability to inhibit TNF secretion from LPS-or lipoteichoic acid-stimulated cells. We found that the presence of 25 ,ug of MAb 5AB3-11 per ml did not affect amounts of TNF secreted by cells incubated with serial dilutions of either LPS (Fig. 3A) or lipoteichoic acid (Fig. 3B ).
MAb 5AB3-11 binds to PI liposomes. We had previously shown that antibodies in polyclonal antisera which inhibit the induction of TNF by malaria toxins bind specifically to liposomes containing PI. To see if MAb 5AB3-11 also bound to PI liposomes, adsorption experiments were performed. MAb 5AB3-11 did not bind to liposomes containing phosphatidylserine, phosphatidylcholine, or cardiolipin but did bind to liposomes containing PI (Fig. 4) water lysed or sonicated. It also inhibited the induction of TNF by partially purified preparations that had been pronase digested ( Table 2 ). All preparations used were from the R29 strain of P. falciparum.
Cross-reactivity of the major malaria toxins in different strains of P. falciparum. It has been observed that different strains of P. falciparum vary in the ability to stimulate TNF secretion (1) . To see if different strains of P. falciparum produce different TNF-inducing toxins, we tested MAb 5AB3-11 to see if it could inhibit TNF induction by whole lysed parasites from several laboratory and wild strains of P. falciparum. MAb 5AB3-11 was found to reduce TNF secretion in response to all strains of Plasmodium parasite tested (Fig. 5) . the IgM isotype. Control IgM MAbs and IgM antibodies isolated from normal mouse serum were not inhibitory, showing that the inhibition was not a general property of this isotype. No protein contaminants were detected when the purified IgM preparations were analyzed by SDS-PAGE, indicating that the inhibitory effect was mediated by antibody.
Only 1 to 2 ,ug of MAb 5AB3-11 per ml was required to reduce malaria toxin-induced TNF production by 50%, showing that it was active at a nanomolar concentration. We note that a similar concentration of a MAb that recognizes the lipid A portion of LPS is required to inhibit LPS-induced TNF secretion (10) . However, this provides only a limited measure of antibody activity in that the inhibitory activity of MAb 5AB3-11 could be overcome by increasing the concentration of malaria toxins. Since we do not know the relationship between the concentration of malaria toxins and TNF production, we cannot calculate the amount of toxin bound by a given concentration of MAb. A better measure of the inhibitory activity of the antibody is provided by the data in Fig. 1B , which shows that 50 times as much toxin was needed to stimulate a given level of TNF when 25 jig of MAb 5AB3-11 per ml was present.
MAb 5AB3-11 did not inhibit TNF production in response to either LPS or lipoteichoic acid, excluding the possibility that the MAb was nonspecifically inhibitory or toxic to cells. The inhibitory activity could not be explained by the MAb binding to macrophage receptors, as cells pretreated with this MAb responded to the subsequent addition of malaria toxins. Furthermore, the MAb did not bind to activated Mono Mac 6 cells or to human mononuclear cells in adsorption experiments. These observations suggest that MAb 5AB3-11 acts by binding to critical epitopes on the TNF-inducing factors derived from malaria-infected erythrocytes.
Although the TNF-inducing activity of malaria toxins is resistant to extensive digestion with mixed proteases, the malaria toxins seem to be associated with a protein component (7) . However, we have two reasons to believe that MAb 5AB3-11 does not bind to protein epitopes on the malaria toxins. First, we showed that MAb 5AB3-11 inhibited partially KLH-PI conjugate. Inhibitory MAbs were also raised after immunization with lysates of P. falciparum-infected erythrocytes. In preliminary studies these MAbs showed the same properties as MAb 5AB3-11; namely, they did not inhibit TNF secretion induced by LPS or lipoteichoic acid and bound specifically to PI liposomes (data not shown). Furthermore, the properties of MAb 5AB3-11 are similar to those observed for the inhibitory antibodies that are found in either polyclonal antisera raised to malaria toxins (3) or sera from malaria patients (2) .
In most of our experiments we used partially purified malaria toxins that we believe contain the major TNF-inducing component in P. falciparum-infected erythrocytes. MAb 5AB3-11 also inhibited the induction of TNF by whole parasitized cells that had been either water lysed or sonicated, showing that within the R29 strain of P. falciparum all major TNF-inducing factors contain a common PI-like epitope. Furthermore, MAb 5AB3-11 inhibited the induction of TNF by different laboratory strains of P. falciparum originating from Malaya, Brazil, The Gambia, and Thailand. It also inhibited TNF-induction by wild isolates from Kenya and The Gambia (data not shown). These results consolidate our conclusion based on studies using polyclonal antisera that the major TNF-inducing toxins from different Plasmodium parasites contain an antigenically conserved epitope (3, 4) . The conservation of an active moiety in different Plasmodium strains and species is analogous to the conservation of the active moiety of This study concentrates on the ability of MAb 5AB3-11 to modulate TNF secretion by human monocytes in response to toxins of P. falciparum-infected erythrocytes. We have focused on TNF because it appears to be a critical mediator of malaria fever (17) and because there is both clinical and experimental evidence that excessive TNF production may be an important factor in the pathogenesis of cerebral malaria. However, it is important to recognize that other pyrogenic cytokines such as interleukin-1, interleukin-6, and lymphotoxin are also released in malaria; furthermore, cell types other than the monocytemacrophage series, particularly lymphocytes and endothelial cells, may be involved in cytokine production during this infection. MAbs against major cytokine-inducing toxins provide an essential tool in investigating the molecular pathogenesis of infection and may lead to new forms of treatment for life-threatening complications of malaria.
